A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)
I6T-MC-AMBI - ClinicalTrials.gov - NCT04469062
The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).
Trial Summary
Age Range
18 - 80 yearsConditions the trial is for
What the trial is testing?
Could I receive a Placebo?
YesEnrollment Goal
Trial Dates
Apr 20, 2021 - Jun 2024How long will I be in the trial?
This study will last about 68 weeks and include at least 19 visits.Trial Phase
IIILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo